Description

KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine[1].—COVID-19-immunoregulation–C118H201N29O36S—-[1]Huang EYC, et, al. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides. WO2018144775A1.–145019-94-9–2634.10—-OC(C=C1)=CC=C1C[C@H](NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@@H](N)CCSC)=O)=O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(O)=O)CCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer; Inflammation/Immunology–10 mM in DMSO–Others—-Others–Peptides